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Minimization cost analysis of hospitalization of 40 patients
affected by hemopoietic malignancies that underwent autol-
ogous bone marrow transplantation has been performed.
Clinical records of 27 patients treated with Filgrastim have
been compared with records of 13 patients not treated. The
retrospective comparative analysis included days of hospi-
talization, antibiotic therapy, nursing time, transfusion epi-
sodes, microbiological cultures required. Overall average
hospitalization cost since transplantation for treated patients
was £65,537,774 versus £69,479,878 (p  0.004). Average
hospitalization time since transplantation for treated pa-
tients was 29.3 days versus 32.7 for not treated. Thus, hos-
pitalization after transplantation was 3.4 days (HR 5.3;
95% C.I. 2.0 to 13.9) shorter for treated, accounting for a
10.4% saving in hospitalization time. Treated patients had
average 5.6 days less in sterile room (HR 5.0; 95% C.I. 2.0
to 12.4). Every treated patient hospitalization raised savings
for at least £3.942.104, taking into account the average sav-
ings in hospitalization days after transplantation. Moreover,
Filgrastim use lead to overall and “sterile” nursing timesav-
ings of 6.5% and 16.8%, results in accordance with shorter
hospitalization. Our results are similar to those reported by
other studies. Suitable use of Filgrastim, reducing hospital-
ization length and disease course, appears to be a valid way
to improve health-care efficiency.
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Douillard et al. (1999), have reported a multicenter, ran-
domized, controlled open label study comparing irinote-
can (Campto®) in combination with 5-fluorouracil (5-
FU) and folinic acid (FA) therapy with fluorouracil/FA
alone as first line treatment for metastatic colorectal can-
cer. They concluded that irinotecan in combination with
5-FU offered consistent significant advantages in terms of
efficacy and clinical benefit over single agent 5-FU with-
out any detrimental effects upon quality of life. We aim
to relate these data to relevant costs within the UK and to
evaluate the economic implications of the difference in
survival between the two treatment arms from the view-
point of a UK NHS commissioner. This work develops
the second line assessment of irinotecan by Iveson et al.
(1999) in the EJC, which concluded that irinotecan
achieved results of £14,000 per life year saved in the sec-
ond line setting. This cost-effectiveness analysis compares
the economic implications of replacing 5-FU therapy as a
single agent (de Gramont regimen or AIO regimen) plus
folinic acid rescue with irinotecan in combination with
5-FU/FA (de Gramont regimen, or AIO regimen). Drug ac-
quisition costs are derived from the British National For-
mulary (March 1999); unit costs for clinical consultations
and services are derived from relevant 1997/1998 cost
databases. Costs associated with treatment delivery and
disease complications are also considered. Indirect costs
although important are not included, in line with the
viewpoint of commissioners within the NHS. Although
cumulative drug acquisition costs per patient are higher
with irinotecan and 5-FU/FA than with infusional 5-FU/
FA therapy alone, these costs are at least partially offset
by lower cumulative costs per patient associated with
treatment of complications in the irinotecan plus 5-FU/
FA arm than in the 5-FU/FA alone arm.
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OBJECTIVE: Lung cancer is a major cause of death in the
UK and small cell lung cancer (SCLC) represents about
20% of primary lung tumors. The costs associated with the
management of SCLC are significant, however few studies
have been conducted in the UK to determine their true ex-
tent. The aim of this study was to obtain an estimate of the
current patterns of treatment and associated resource use
and costs for SCLC in the UK.
METHODS: Study sites were two hospitals in Newcastle-
upon-Tyne. A focus group meeting with local clinicians
clarified the expected pathways of SCLC care. Forms for
retrospective patient record data extraction were developed
on a per treatment phase basis. Data was collected on a
consecutive series of 106 patients diagnosed with SCLC be-
tween 1994 and 1997. Unit costs were determined from lo-
cal hospital accounts and secondary sources.
